A novel method predicting clinical response using only background clinical data in RA patients before treatment with infliximab

被引:16
|
作者
Miyoshi, Fumihiko [1 ,5 ]
Honne, Kyoko [2 ]
Minota, Seiji [2 ]
Okada, Masato [3 ]
Ogawa, Noriyoshi [4 ]
Mimura, Toshihide [1 ]
机构
[1] Saitama Med Univ, Dept Rheumatol & Appl Immunol, Fac Med, Morohongo 38, Moroyama, Saitama 3500495, Japan
[2] Jichi Med Univ, Div Rheumatol & Clin Immunol, Shimotsuke, Tochigi, Japan
[3] St Lukes Int Hosp, Immunorheumatol Ctr, Tokyo, Japan
[4] Hamamatsu Univ Sch Med, Internal Med 3, Div Rheumatol & Immunol, Hamamatsu, Shizuoka, Japan
[5] Mitsubishi Tanabe Pharma Corp, Sohyaku Innovat Res Div, Biol Res Labs, Saitama, Japan
关键词
Clinical data; Infliximab; Machine-learning; Rheumatoid arthritis; The prediction of clinical response; MONOCLONAL-ANTIBODY; EXPRESSION PROFILE; BLOOD-CELLS; RESPONSIVENESS; THERAPIES; CANCER;
D O I
10.3109/14397595.2016.1168536
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives: The aim of the present study was to generate a novel method for predicting the clinical response to infliximab (IFX), using a machine-learning algorithm with only clinical data obtained before the treatment in rheumatoid arthritis (RA) patients. Methods: We obtained 32 variables out of the clinical data on the patients from two independent hospitals. Next, we selected both clinical parameters and machine-learning algorithms and decided the candidates of prediction method. These candidates were verified by clinical variables on different patients from two other hospitals. Finally, we decided the prediction method to achieve the highest score. Results: The combination of multilayer perceptron algorithm (neural network) and nine clinical parameters shows the best accuracy performance. This method could predict the good or moderate response to IFX with 92% accuracy. The sensitivity of this method was 96.7%, while the specificity was 75%. Conclusions: We have developed a novel method for predicting the clinical response using only background clinical data in RA patients before treatment with IFX. Our method for predicting the response to IFX in RA patients may have advantages over the other previous methods in several points including easy usability, cost-effectiveness and accuracy.
引用
收藏
页码:813 / 816
页数:4
相关论文
共 50 条
  • [21] Immunophenotyping in routine clinical practice for predicting treatment response and adverse events in patients with MS
    Zrzavy, Tobias
    Rieder, Kerstin
    Wuketich, Viktoria
    Thalhammer, Renate
    Haslacher, Helmuth
    Altmann, Patrick
    Kornek, Barbara
    Krajnc, Nik
    Monschein, Tobias
    Schmied, Christiane
    Zebenholzer, Karin
    Zulehner, Gudrun
    Berger, Thomas
    Rommer, Paulus
    Leutmezer, Fritz
    Bsteh, Gabriel
    FRONTIERS IN NEUROLOGY, 2024, 15
  • [22] A Semi-Supervised Method for Predicting Cancer Survival Using Incomplete Clinical Data
    Hassanzadeh, Hamid Reza
    Phan, John H.
    Wang, May D.
    2015 37TH ANNUAL INTERNATIONAL CONFERENCE OF THE IEEE ENGINEERING IN MEDICINE AND BIOLOGY SOCIETY (EMBC), 2015, : 210 - 213
  • [23] Leverage radiomic and clinical data in predicting SRS treatment outcomes in patients with brain mets
    Carloni, G.
    Marvaso, G.
    Garibaldi, C.
    Zaffaroni, M.
    Volpe, S.
    Pepa, M.
    Raimondi, S.
    Lo Presti, G.
    Positano, V.
    Orecchia, R.
    Jereczek-Fossa, B. A.
    RADIOTHERAPY AND ONCOLOGY, 2022, 170 : S1590 - S1591
  • [24] Predicting treatment effects using biomarker data in a meta-analysis of clinical trials
    Li, Y.
    Taylor, J. M. G.
    STATISTICS IN MEDICINE, 2010, 29 (18) : 1875 - 1889
  • [25] WHAT TREATMENT GIVES THE BEST CLINICAL RESPONSE AFTER CESSATION OF JAKI THERAPY IN PATIENTS WITH RA? DATA OF THE TARDIS-RA REGISTRY, A NATIONWIDE BELGIAN BIOLOGIC REGISTRY
    De Cock, D.
    Durez, P.
    Badot, V.
    Westhovens, R.
    Verschueren, P.
    ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 : 626 - 627
  • [26] Remission and major clinical response in patients with active rheumatoid arthritis (RA) after treatment with adalimumab (Humira®).
    Burmester, G. M.
    Ferraccioli, G. F.
    Flipo, R-M
    Kary, S.
    Kupper, H.
    ARTHRITIS AND RHEUMATISM, 2006, 54 (09): : S377 - S377
  • [27] Remission and major clinical response in active rheumatoid arthritis (RA) patients after adalimumab (Humira®) treatment
    Burmester, G. M.
    Wordsworth, P.
    McKenna, F.
    Farraccioli, G. F.
    Flipo, R. -M.
    Kary, S.
    Kupper, H.
    RHEUMATOLOGY, 2007, 46 : I28 - I29
  • [28] Predicting Clinical Anticancer Drug Response of Patients by Using Domain Alignment and Prototypical Learning
    Peng, Wei
    Chen, Chuyue
    Dai, Wei
    Yu, Ning
    Wang, Jianxin
    IEEE JOURNAL OF BIOMEDICAL AND HEALTH INFORMATICS, 2025, 29 (02) : 1534 - 1545
  • [29] Predicting pathological response to neoadjuvant chemotherapy in breast cancer patients based on imbalanced clinical data
    Ting Gao
    Yaguang Hao
    Haipeng Zhang
    Lina Hu
    Hongzhi Li
    Hui Li
    LiHong Hu
    Bing Han
    Personal and Ubiquitous Computing, 2018, 22 : 1039 - 1047
  • [30] Relationship between serum trough infliximab levels, pretreatment C reactive protein levels, and clinical response to infliximab treatment in patients with rheumatoid arthritis
    Wolbink, GJ
    Voskuyl, AE
    Lems, WF
    de Groot, E
    Nurmohamed, MT
    Tak, PP
    Dijkmans, BAC
    Aarden, L
    ANNALS OF THE RHEUMATIC DISEASES, 2005, 64 (05) : 704 - 707